What is esketamine and what does it treat? Esketamine is an intranasal antidepressant medication that works in the brain. It is FDA approved for the treatment of major depressive disorder (MDD) with suicidal thoughts and behavior as well as treatment-resistant depression (TRD) in conjunction with an oral antidepressant.
Ketamine troches are small, flavored lozenges designed to dissolve under the tongue (sublingual) or between the cheek and gum (buccal), allowing the medication to be absorbed directly into the bloodstream through oral mucosa. This method bypasses the digestive system and first-pass liver metabolism, providing a smoother onset and more efficient absorption compared to oral pills. Troches are commonly used for conditions such as depression, anxiety, PTSD, and chronic pain, often as part of a broader ketamine-assisted therapy plan.
Ketamine acts on NMDA receptors in the brain, producing rapid improvements in mood and pain perception. Sublingual absorption allows for a gradual onset of effects, typically starting within 10–30 minutes, with primary effects lasting 1–2 hours, though residual benefits may persist for days or weeks. The experience can include mild dissociation, altered perception, or emotional relief, which is generally temporary and resolves within a few hours.
There is no standard dose, as ketamine troche therapy is highly individualized. Clinicians often start with a low dose and adjust based on effectiveness and tolerance. Common dosing ranges include:
Ketamine troches are off-label for mental health and pain conditions, meaning they are prescribed based on clinical judgment rather than FDA approval for these uses. Temporary side effects may include: